The making of bispecific antibodies

mAbs

Volumn 9, Issue 2, 2017, Pages 182-212

  Brinkmann, Ulrich ^a   Kontermann, Roland E ^b  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Appended IgG; bispecific antibodies; Fab; Fc heterodimerization; fusion proteins; immunoglobulin; scFv

Indexed keywords

ANTIBODY CONJUGATE; BISPECIFIC ANTIBODY; BLINATUMOMAB; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN A; RECOMBINANT ANTIBODY; SCAFFOLD PROTEIN; SERUM ALBUMIN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; AFFINITY CHROMATOGRAPHY; ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CELL PHAGOCYTOSIS; GENETIC ENGINEERING; HEK293 CELL LINE; HUMAN; NATURAL KILLER CELL; REVIEW; ANIMAL;

ANIMALS; ANTIBODIES, BISPECIFIC; HUMANS;

EID: 85011347310     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1268307     Document Type: Review

References (297)

1. Dhimolea E, Reichert JM. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. MAbs 2012; 4:4-13; PMID:22327426; http://dx.doi.org/10.4161/mabs.4.1.18821
2. Garber K. Bispecific antibodies rise again. Nat Rev Drug Discov 2014; 13:799-801; PMID:25359367; http://dx.doi.org/10.1038/nrd4478
3. Sheridan C. Amgen's bispecific antibody puffs across finish line. Nat Biotechnol 2015; 33:219-21; PMID:25748895; http://dx.doi.org/10.1038/nbt0315-219
4. Riethmüller G. Symmetry breaking:bispecific antibodies, the beginnings, and 50 years on. Cancer Immunity 2012; 12:12; PMID:22896757
5. Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys 1961; 93:460-2; PMID:13729244
6. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7; PMID:1172191
7. Brennan M, Davison PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 1985; 229:81-3; PMID:3925553
8. Milstein C, Cuello AC. Hybrid hyridomas and their use in immunohistochemistry. Nature 1983; 305:537-40; PMID:6137772
9. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065
10. Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005; 26:1-9; PMID:15659107; http://dx.doi.org/10.1111/j.1745-7254.2005.00008.x
11. Tiller KE, Thessier PM. Advances in antibody design Annu Rev Biomed Eng 2016; 17:191-216; PMID:26274600; http://dx.doi.org/10.1146/annurev-bioeng-071114-040733
12. Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs:generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol 2016; 40:24-35; PMID:26963133; http://dx.doi.org/10.1016/j.coi.2016.02.006
13. de Gast GC, van de Winkel JG, Bast BE. Clinicial perspectives of bispecific antibodies in cancer. Cancer Immunol Immunother 1997; 45:121-3; PMID:9435853
14. van Spries AB, van Ojik HH, van de Winkel JG. Immunotherapeutic perspective for bispecific antibodies. Immunol Today 2000; 21:391-7; PMID:10916142
15. Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, van der Vliet HJ. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol hematol 2014:92:153-65,DOI:10.1016/j.critrevonc.2014.08.003; PMID:25195094
16. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011; 22:868-76; PMID:21862310; http://dx.doi.org/10.1016/j.copbio.2011.06.012
17. Kontermann RE. Dual targeting strategies with bispecific antibodies. mAbs 2012; 4:182-97
18. Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014; 81:49-60; PMID:24411731; http://dx.doi.org/10.1016/j.neuron.2013.10.061
19. Pardridge WM. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain penetrating bi-specific antibodies. Expert Opin Biol Ther 2016; 7:1-14; PMID:27572805; http://dx.doi.org/10.1080/14712598.2016.1230195
20. Kufer P, Lutterbüse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 2004; 22:238-44; PMID:15109810; http://dx.doi.org/10.1016/j.tibtech.2004.03.006
21. Chames P, Baty D. Bispecific antibodies for cancer therapy:the light at the end of the tunnel? MAbs 2009; 1:539-47; PMID:20073127
22. Müller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy:current perspectives. BioDrugs 2010; 24:89-98; PMID:20556545; http://dx.doi.org/10.1007/s12033-010-9298-x
23. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities:bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31:621-32; PMID:24094861; http://dx.doi.org/10.1016/j.tibtech.2013.08.007
24. Kontermann R, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015; 20:838-47; PMID:25728220; http://dx.doi.org/10.1016/j.drudis.2015.02.008
25. Weidle UH, Kontermann RE, Brinkmann U. Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol 2014; 41:653-60; PMID:25440609; http://dx.doi.org/10.1053/j.seminoncol.2014.08.004
26. Stanimirovic D, Kemmerich K, Haqqani AS, Farrington GK. Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. Adv Pharmacol 2014; 71:301-35; PMID:25307221; http://dx.doi.org/10.1016/bs.apha.2014.06.005
27. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67:95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
28. Nogami K. Bispecific antibody mimicking factor VIII. Thromb Res 2016; 141 Suppl 2:S34-35; PMID:27207420; http://dx.doi.org/10.1016/S0049-3848(16)30361-9
29. Cao Y, Suresh MR. Bispecific antibodies as novel bioconjugates. Bioconjugat Chem 1998; 9:635-44; PMID:9815155; http://dx.doi.org/10.1021/bc980044l
30. Thakur A, Lum LG. Cancer therapy with bispecific antibodies:clinical experience. Curr Opin Mol Ther 2010; 12:340-9; PMID:20521223
31. Ellerman D, Scheer JM. Generation of bispecific antibodies by chemical conjugation. In. Bispecific antibodies (ed Kontermann RE,), Springer-Verlag Berlin Heidelberg, 2011; 47-63; http://dx.doi.org/10.1007/978-3-642-20910-9_3
32. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C, Levin NJ, Shields MJ, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci USA 2010; 107:22611-6; PMID:21149738; http://dx.doi.org/10.1073/pnas.1016478108
33. Schaefer W, Völger HR, Lorenz S, Imhof-Jung S, Regula JT, Klein C, Mølhøj M. Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry. MAbs 2016; 8:49-55; PMID:26496506; http://dx.doi.org/10.1080/19420862.2015.1111498
34. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. ScFv antibody:principles and clinical application. Clin Dev. Immun 2012; 2012:980250; PMID:22474489; http://dx.doi.org/10.1155/2012/980250
35. Hayden MS, Linsley PS, Gayle MA, Bajorath J, Brady WA, Norris NA, Fell HP, Ledbetter JA, Gilliland LK. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther Immunol 1994; 1:3-15; PMID:7584477
36. Mallender WD, Voss EW, Jr. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem 1994; 269:199-206; PMID:8276795
37. Gruber M, Schodin BA, Wilson ER, Kranz DM. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol 1994; 152:5368-74; PMID:8189055
38. Brandao JG, Scheper RK, Lougheed SM, Curiel DT, Tillman BW, Gerritsen WR, van den Eertwegh AJ, Pinedo HM, Haisma HJ, de Gruijl TD. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 2003; 21:2268-72; PMID:12744857
39. Korn T, Nettelbeck DM, Völkel T, Müller R, Kontermann RE. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells:a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 2004; 6:642-51; PMID:15170735; http://dx.doi.org/10.1002/jgm.555
40. Neri D, Momo M, Prospero T, Winter G. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol 1995; 246:367-73; PMID:7533215; http://dx.doi.org/10.1006/jmbi.1994.0091
41. Mack M, Riethmüller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995; 92:7021-5; PMID:7624362
42. De Jonge J, Brissinck J, Heirman C, Demanet C, Leo O, Moser M, Thielemans K. Production and characterization of bispecific single-chain antibody fragments. Mol Immunol 1995; 32:1405-12; PMID:8643110
43. Kufer P, Mack M, Gruber R, Lutterbüse R, Zettl F, Rietmühler G. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother 1997; 45:193-7; PMID:9435872
44. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001; 166:6112-7; PMID:11342630
45. Grosse-Hovest L, Müller S, Minoia R, Wolf E, Zakhartchenko V, Wenigerkind H, Lassnig C, Besenfelder U, Müller M, Lytton SD, et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci USA 2004; 101:6858-63; PMID:15105446; http://dx.doi.org/10.1073/pnas.0308487101
46. Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer 2004; 100:1095-103; PMID:14983507; http://dx.doi.org/10.1002/cncr.20060
47. Segal DM, Sconocchia G, Titus JA, Jost CR, Kurucz I. Alternative triggering molecules and singe chain bispecific antibodies. J Hematother 1995; 4:377-82; PMID:8581372; http://dx.doi.org/10.1089/scd.1.1995.4.377
48. Fang M, Zhao R, Yang Z, Zhang Z, Li H, Zhang XT, Lin Q, Huang HL. Characterization of an anti-human ovarian carcinomaxanti-human CD3 bispecific single-chain antibody with an albumin-original interlinker. Gynecol Oncol 2004; 92:135-46; PMID:14751149
49. Schmohl JU, Gleason MK, Dougherty PR, Miller JS, Vallera DA. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells. Target Oncol 2016; 11:353-61; PMID:26566946; http://dx.doi.org/10.1007/s11523-015-0391-8
50. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs:bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005; 10:1237-44; PMID:16213416; http://dx.doi.org/10.1016/S1359-6446(05)03554-3
51. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69:4941-4; PMID:19509221; http://dx.doi.org/10.1158/0008-5472.CAN-09-0547
52. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 2015; 93:290-6; PMID:25367186; http://dx.doi.org/10.1038/icb.2014.93
53. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab:a historical perspective. Pharmcol Ther 2012; 136:334-42; PMID:22940266; http://dx.doi.org/10.1016/j.pharmthera.2012.07.013
54. Stieglmaier J, Benjamin J, Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther 2015; 15:1093-9; PMID:25971805; http://dx.doi.org/10.1517/14712598.2015.1041373
55. Newman MJ, Benani DJ. A review of blinatumomab, a novel immunotherapy. J Oncol Pharm Pract 2016; 22:639-45; PMID:26607163; http://dx.doi.org/10.1177/1078155215618770
56. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119:6226-33; PMID:22592608; http://dx.doi.org/10.1182/blood-2012-01-400515
57. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia:a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16:57-66; PMID:25524800; http://dx.doi.org/10.1016/S1470-2045(14)71170-2
58. Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, et al. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J. Immunother 2008; 31:871-84; PMID:18833000
59. Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Mentz K, Singer H, Stockmeyer B, Hillen W, et al. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 2011; 3:21-30; PMID:21081841
60. Ahmed M, Cheng M, Cheung IY, Cheung NK. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. Oncoimmunology 2015; 4:e989776; PMID:26137406
61. Kügler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I.Singer H, Oduncu F, Stockmeyer B, et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 2010; 150:574-586; PMID:20636437
62. Igawa T, Tsunoda H, Kikuchi Y, Yoshida M, Tanaka M, Koga A, Sekimori Y, Orita T, Aso Y, Hattori K, et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Eng DesSel 2010; 23:667-77; PMID:20576629; http://dx.doi.org/10.1093/protein/gzq034
63. Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G. The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genomics Proteomics 2013; 10:155-68; PMID:23893924
64. Saerens D, Ghassebeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008; 8:600-8; PMID:18691671; http://dx.doi.org/10.1016/j.coph.2008.07.006
65. Conrath EK, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001; 276:7346-50; PMID:11053416
66. Simmons DP, Abregu FA, Krishnan UV, Proll DF, Streltsov VA, Doughty L, Hattarki MK, Nuttall SD. Dimerisation strategies for shark IgNAR single domain antibody fragments. J Immunol Methods 2006; 315:171-84; PMID:16962608; http://dx.doi.org/10.1016/j.jim.2006.07.019
67. De Bernardis F, Liu H, O'Mahony R, La Valle R, Bartollino S, Sandini S, Grant S, Brewis N, Tomlinson I, Basset RC, et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 2007; 195:149-57; PMID:17152019; http://dx.doi.org/10.1086/509891
68. Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis 2014; 210:964-72; PMID:24683195; http://dx.doi.org/10.1093/infdis/jiu196
69. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther 2015; 17:135; PMID:25994180; http://dx.doi.org/10.1186/s13075-015-0651-0
70. Harmsen MM, Fijten HP, Dekker A, Eblé PL. Passive immunization of pigs with bispecific llama single-domain antibody fragments against foot-and-mouth disease and porcine immunoglobulin. Vet Microbiol 2008; 132:56-64; PMID:18534789; http://dx.doi.org/10.1016/j.vetmic.2008.04.030
71. Holliger P, Prospero T, Winter G. “Diabodies:” small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90:6444-8; PMID:8341653
72. Wu C. Diabodies:molecular engineering and therapeutic applications. Drug News Perspect 2009; 22:453-8; PMID:20016854
73. Perisic O, Webb PA, Holliger P, Winter G, Williams RL. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994; 2:1217-26; PMID:7704531
74. Holliger P, Brissinck J, Williams RL, Thielemans K, Winter G. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 1996; 9:299-305; PMID:8736497
75. Atwell JL, Pearce LA, Lah M, Gruen LC, Kortt AA, Hudson PJ. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. Mol Immunol 1996; 33:1301-12; PMID:9171890
76. Kontermann RE, Wing MG, Winter G. Complement recruitment using bispecific diabodies. Nat Biotechnol 1997; 15:629-31; PMID:9219263; http://dx.doi.org/10.1038/nbt0797-629
77. Kontermann RE, Martineau P, Cummings CE, Karpas A, Allen D, Derbyshire E, Winter G. Enzyme immunoassays using bispecific diabodies. Immunotechnology 1997; 3:137-44; PMID:9237098
78. Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G, Little M. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000; 60:4336-41; PMID:10969772
79. DeNardo DG, Xiong CY, Shi XB, DeNardo GL, DeNardo SJ. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform:bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm 2001; 16:525-35; PMID:11789029; http://dx.doi.org/10.1089/10849780152752128
80. Lu D, Jimenez X, Witte L, Zhu Z. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun 2004; 318:507-13; PMID:15120630; http://dx.doi.org/10.1016/j.bbrc.2004.04.060
81. Hudson PJ, Kortt AA. High avidity scFv multimers:diabodies and triabodies. J Immunol Meth 1999; 231:177-89; PMID:10648937
82. Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19:effect of valency on cell binding. FEBS Lett 1999; 453:164-8; PMID:10403395
83. Kipriyanov SM, Moldenhauer G, Braunagel M, Reusch U, Cochlovius B, Le Gall F, Kouprianova OA, Von der Lieth CW, Little M. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J Mol Biol 2003; 330:99-111; PMID:12818205
84. Fitzgerald K, Holliger P, Winter G. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 1997; 10:1221-5; PMID:9488147
85. Zhu Z, Presta LG, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997; 6:781-8; PMID:9098887; http://dx.doi.org/10.1002/pro.5560060404
86. Schmiedl A, Breitling F, Dübel S. Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli. Protein Eng 2000; 13:725-34; PMID:11112512
87. Brüsselbach S, Korn T, Völkel T, Müller R, Kontermann RE. Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Targeting. 1999; 4:115-23
88. Korn T, Müller R, Kontermann RE. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 2004; 27:99-106; PMID:14770081
89. Völkel T, Korn T, Bach M, Müller R, Kontermann RE. Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. Protein Eng 2001; 14:815-23; PMID:11739902
90. Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H, Bippes CC, Wehner R, Schmitz M, von Bonin M, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol 2011; 49:474-82; PMID:22014687; http://dx.doi.org/10.1016/j.molimm.2011.09.019
91. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, von der Lieth CW, Matys ER, Little M. Bispecific tandem diabodies for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293:41-56; PMID:10512714
92. Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 2004; 17:357-66; PMID:15126676; http://dx.doi.org/10.1093/protein/gzh039
93. Reusch U, Burkhardt C, Fucet I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Kiprijanov S, Little M, Zhukovsky EA. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 2014; 6:728-39; PMID:24670809; http://dx.doi.org/10.4161/mabs.28591
94. Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015; 125:4024-31; PMID:25887777; http://dx.doi.org/10.1182/blood-2014-12-614636
95. Reusch U, Harrington K, Gudgeon C, Fucek I, Ellwanger K, Weichel M, Knackmuss SH, Zhukovsky EA, Fox JA, Kunkel LA, et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res 2016; 22(23):5829-38; Epub ahead of print; PMID:27189165; http://dx.doi.org/10.1158/1078-0432.CCR-16-0350
96. Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 2010; 399:436-449; PMID:20382161; http://dx.doi.org/10.1016/j.jmb.2010.04.001
97. Moore P, Chichili GR, Huang L, Li H, Burke S, Chen F, et al. Preclinical activity and safety of MGD006, a CD123xCD3 bispecific DART molecule for the treatment of hematological malignancies. Eur J Cancer 2014; 50:48
98. Brien JD, Sukupolvi-Petty S, Williams KL, Lam CY, Schmid MA, Johnson S, Harris E, Diamond MS. Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J. Virol 2013; 87:7747-53; PMID:23658441; http://dx.doi.org/10.1128/JVI.00327-13
99. Rossi EA, Sharkey RM, McBridge W, Karacay H, Zeng L, Hansen HJ, Goldenberg DM, Chang CH. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 2003; 9:3886S-96S; PMID:14506187
100. Rossi EA, Chang CH, Losman MJ, Sharkey RM, Karacay H, McBridge W, Cardillo TM, Hansen HJ, Qu Z, Horak ID, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res 2005; 11:7122s-9s; PMID:16203811; http://dx.doi.org/10.1158/1078-0432.CCR-1004-0020
101. Schoonjans R, Willems A, Schoonooghe S, Fiers W, Grooten J, Mertens N. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 2000; 165:7050-7; PMID:11120833
102. Schoonjans R, Willems A, Schoonooghe S, Leoen J, Grooten J, Mertenss N. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain. Biomol Eng 2001; 17:193-202; PMID:11337278
103. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Fab-scFv fusion protein:an efficient approach to production of bispecific antibody fragments. J Immunol Methods 2002; 267:213-26; PMID:12165442
104. Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008; 111:2211-9; PMID:18025153; http://dx.doi.org/10.1182/blood-2007-08-110072
105. Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, Barbin K, Stein C, Peipp M, Stockmeyer B, et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett 2011; 303:128-39; PMID:21339041; http://dx.doi.org/10.1016/j.canlet.2011.01.020
106. Panke C, Weiniger D, Haas A, Schelter F, Schlothauer T, Bader S, Sircar R, Josel HP, Baer U, Burtscher H, et al. Quantification of cell surface proteins with bispecific antibodies. Protein Eng Des Sel 2013; 26:645-54; PMID:23960142; http://dx.doi.org/10.1093/protein/gzt035
107. Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15:159-63; PMID:9035142; http://dx.doi.org/10.1038/nbt0297-159
108. Li A, Xing J, Li L, Zhou C, Dong B, He P, Li Q, Wang Z. A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells. AMB Express 2016; 6:32; PMID:27112931; http://dx.doi.org/10.1186/s13568-016-0201-4
109. Mayer K, Baumann AL, Grote M, Seeber S, Kettenberger H, Breuer S, Killian T, Schäfer W, Brinkmann U. TriFabs - Trivalent IgG-Shaped Bispecific Antibody Derivatives:Design, Generation, Characterization and Application for Targeted Payload Delivery. Int J Mol Sci 2015; 16:27497-4507; PMID:26593903; http://dx.doi.org/10.3390/ijms161126037
110. Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 1993; 90:7538-42; PMID:8356052
111. Reiter Y, Brinkmann U, Lee B, Pastan I. Engineering antibody Fv fragments for cancer detection and therapy:disulfide-stabilized Fv fragments. Nat Biotechnol 1996; 14:1239-45; PMID:9631086
112. Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs 2015, 7:470-82; PMID:25774965; http://dx.doi.org/10.1080/19420862.2015.1022694
113. Davé E, Adams R, Zaccheo O, Carrington B, Composn JE, Dugdale S, Airey M, Malcolm S, Hailu H, Wild G, et al. Fab-dsFv:a bispecific antibody format with extended serum half-life through albumin binding. MAbs 2016; 8(7):1319-35; epub ahead of print; PMID:27532598; http://dx.doi.org/10.1080/19420862.2016.1210747
114. Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother 2014; 63:437-48; PMID:24531387; http://dx.doi.org/10.1007/s00262-014-1525-z
115. Oates J, Hassan NK, Jakobsen BK. ImmTACs for targeted cancer therapy:Why, what, how, and which. Mol Immunol 2015; 67:67-74; PMID:25708206; http://dx.doi.org/10.1016/j.molimm.2015.01.024
116. Boulter JM, Glick M, Todorov PT, Baston E, Sami M, Rizkallah P, Jakobsen BK. Stable soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng 2003; 16:707-11; PMID:14560057
117. Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148:1547-53; PMID:1531669
118. De Kruif J, Logtenberg T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J Biol Chem 1996; 271:7630-34; PMID:8631798
119. Plückthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997; 3:83-105; PMID:9237094
120. Müller KM, Arndt KM, Plückthun A. A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett 1998; 432:45-49; PMID:9710248
121. Müller KM, Arndt KM, Strittmatter W, Plückthun A. The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett 1998; 422:259-264; PMID:9490020
122. Rozan C, Cornillon A, Pétiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pèlegrin A, Chames P, et al. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther 2013; 12:1481-91; PMID:23757164; http://dx.doi.org/10.1158/1535-7163.MCT-12-1012
123. Yu X, Duval M, Gawron M, Posner MR, Cavacini LA. Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition. J Immunol Res 2016; 2016:9425172; PMID:27419146; http://dx.doi.org/10.1155/2016/9425172
124. Rossi EA, Goldenberg DM, Cardillo TM, McBridge WJ, Skarkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 2006; 103:68416846; PMID:16636283; http://dx.doi.org/10.1073/pnas.0600982103
125. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBridge WJ, Chang CH, Goldenberg DM. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008; 68:5282-90; PMID:18593929; http://dx.doi.org/10.1158/0008-5472.CAN-08-0037
126. Rossi EA, Goldenberg DM, Chang CH. Complex and defined biostructures with the dock-and-lock method. Trends Pharmacol Sci 2012; 33:474-81; PMID:22739259; http://dx.doi.org/10.1016/j.tips.2012.06.001
127. Sharkey RM, Rossi EA, McBridge WJ, Chang CH, Goldenberg DM. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 2010; 40:190-203; PMID:20350628; http://dx.doi.org/10.1053/j.semnuclmed.2009.12.002
128. Rossi DL, Rossi EA, Cardillo TM, Goldenberg DM, Chang CH. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. Mabs 2014; 6:381-91; PMID:24492297; http://dx.doi.org/10.4161/mabs.27385
129. Deyev SM, Waibel R, Lebedenko EN, Schubiger AP, Plückthun A. Design of mutlivalent complexes using the barnase*barstar module. Nat Biotechnol 2003; 21:1486-92; PMID:14634668; http://dx.doi.org/10.1038/nbt916
130. Semenyuk EG, Stremovskiy OA, Edelweiss EF, Shirshikova OV, Balandin TG, Buryanov YI, Deyev SM. Expression of single-chain antibody-barstar fusion in plants. Biochimie 2007; 89:31-8; PMID:16938381
131. Rossi EA, Chang CH, Cardillo TM, Goldenberg DM. Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties. Bioconjug Chem 2012; 24:63-71; PMID:23116517; http://dx.doi.org/10.1021/bc300488f
132. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta 2013; 1830:526-5534; PMID:23639804; http://dx.doi.org/10.1016/j.bbagen.2013.04.023
133. Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282:12650-60; PMID:17347147; http://dx.doi.org/10.1074/jbc.M700820200
134. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11-0820
135. Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 2005; 11:3879-88; PMID:15897589; http://dx.doi.org/10.1158/1078-0432.CCR-04-2290
136. Song J, Wang X, Lei C, Piao J, Yin C, Zhang Z, Lin Q, Huang H. Fusion of chemotactic peptide to a single-chain bi-specific antibody (scBsAb) potentiates its cytotoxicity to target tumour cells. Biotechnol Appl Biochem 2006; 45:147-54; PMID:16836487; http://dx.doi.org/10.1042/BA20060060
137. Keck PC, Huston JS. Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region. Biophys J 1996; 71:2002-11; PMID:8889174; http://dx.doi.org/10.1016/S0006-3495(96)79398-0
138. Lobner E, Traxlmayr MW, Obinger C, Hasenhindl C. Engineered IgG1-Fc - one fragment to bind them all. Immunol Rev 2016; 270:113-31; PMID:26864108; http://dx.doi.org/10.1111/imr.12385
139. Suresh MR, Cuello AC, Milstein C. Bispecific monoclonal antibodies from hybrid hybridoma. Methods Enzymol 1986; 121:210-28; PMID:3724461
140. Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010; 2:309-19; PMID:20418662
141. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155:219-25; PMID:7602098
142. Dall'Acqua W, Simon AL, Mulkerrin MG, Carter P. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers. Biochemistry 1998; 37:9266-73; PMID:9649307; http://dx.doi.org/10.1021/bi980270i
143. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834
144. Chen C, Zhang Y, Zhang Y, Li J, Tsao SW, Zhang MY. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Mol Cancer Ther 2013; 13:90-100; PMID:24227890; http://dx.doi.org/10.1158/1535-7163.MCT-13-0558
145. Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26-35; PMID:9231898; http://dx.doi.org/10.1006/jmbi.1997.1116
146. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-681; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
147. Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, Sandoval W, Kelley RF, Scheer JM. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs 2013; 5:872-81; PMID:23995614; http://dx.doi.org/10.4161/mabs.26307
148. Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. dentification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8:e57479; PMID:23468998; http://dx.doi.org/10.1371/journal.pone.0057479
149. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31:753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621
150. Juntilla TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. 2014; 74:5561-71; PMID:25228655; http://dx.doi.org/10.1158/0008-5472.CAN-13-3622-T
151. Sun JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CY, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, et al. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest 2015; PMID:26413868; http://dx.doi.org/10.1172/JCI82314125:4077-4090
152. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004; 279:53907-14; PMID:15471859; http://dx.doi.org/10.1074/jbc.M407888200
153. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, Lee WP, Zhang J, Sharma N, Lu Y, et al. Development of two-part strategies to identify a therapeutic bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850-9; PMID:20444694; http://dx.doi.org/10.1074/jbc.M110.113910
154. Spiess C, Bevers J, 3rd, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, et al. Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J Biol Chem 2013; 288:26583-93; PMID:23880771; http://dx.doi.org/10.1074/jbc.M113.480483
155. Xie Z, Guo N, Yu M, Hu M, Shen B. A new format of bispecific antibody:highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 2005; 296:96-101; PMID:15680154; http://dx.doi.org/10.1016/j.jim.2004.11.005
156. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, et al. A two-in-one antibody against HER3 and EGFR has superor inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
157. Castoldi R, Jucknischke U, Pradel LP, Arnold E, Klein C, Scheiblich S. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Eng Des Sel 2012; 25:551-9
158. Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel 2012; 25:571-80; PMID:22976197; http://dx.doi.org/10.1093/protein/gzs064
159. Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA 2013; 110:E2987-2996; PMID:23882082; http://dx.doi.org/10.1073/pnas.1302725110
160. Schanzer JM, Wartha K, Croasdale R, Moser S, Künkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, et al. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. J Biol Chem 2014; 289:18693-796; PMID:24841203; http://dx.doi.org/10.1074/jbc.M113.528109
161. Xu Y, Lee J, Tran C, Heibeck TH, Wang WD, Yang J, Stafford RL, Steiner AR, Sato AK, Hallam TJ, et al. Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system. MAbs 2015; 7:231-42; PMID:25427258; http://dx.doi.org/10.4161/19420862.2015.989013
162. Taylor K, Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H, Munro TP, Mahler SM. Nanocell targeting using engineered bispecific antibodies. MAbs 2015; 7:53-65; PMID:25523746; http://dx.doi.org/10.4161/19420862.2014.985952
163. Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivaci A, Muchhal US, Karki S, Chu SY, Lazar GA. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3:546-557; PMID:22123055; http://dx.doi.org/10.4161/mabs.3.6.18123
164. Von Kreudenstein TS, Escobar-Carbrera E, lario PI, D'Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH, et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability:quality by molecular design. MAbs 2013; 5:646-54; PMID:23924797; http://dx.doi.org/10.4161/mabs.25632
165. Woods RJ, Xie MH, von Kreudenstein TS, Ng GY, Dixit SB. LC-MS characterization and purity assessment of a prototype bispecific antibody. MAbs 2013; 5:711-22; PMID:23884083; http://dx.doi.org/10.4161/mabs.25488
166. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects:applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382
167. Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem 2015; 290:7535-62; PMID:25583986; http://dx.doi.org/10.1074/jbc.M114.620260
168. Florio M, Guaneskaran K, Stolina M, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, Tan HL, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun 2016; 7:11505; PMID:27230681; http://dx.doi.org/10.1038/ncomms11505
169. Geuijen C, Rovers E, Nijhuis R, Visser T, den Blanken-Smit R, Barelink W, et al. Preclinical activity of MCLA-128, an ADCC enhanced human bispecific IgG1 antibody targeting the HER2:HER3 heterodimer. Journal of Clinical Oncology 2014; 32:suppl:560
170. Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012.04.020
171. Choi HJ, Kim YJ, Lee S, Kim YS. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol Cancer Ther 2013; 12:2748-59; PMID:24132142; http://dx.doi.org/10.1158/1535-7163.MCT-13-0628
172. Choi HJ, Seok SH, Kim YJ, Seo Md, Kim YS. Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation. Mol Immunol 2015; 65:377-83; PMID:25743157; http://dx.doi.org/10.1016/j.molimm.2015.02.017
173. Choi HJ, Kim YJ, Choi DK, Kim YS. Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening. PLoS One 2015; 10:e0145349; PMID:26675656
174. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinze P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-7; PMID:17872445; http://dx.doi.org/10.1126/science.1144603
175. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
176. Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, Gerritsen AF, Schuurman J, Parren PW. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc 2014; 9:2450-63; PMID:25255089; http://dx.doi.org/10.1038/nprot.2014.169
177. Gramer MJ, van den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange:scalability from bench to large-scale manufacturing by application of standard approaches. MAbs 2013, 5:962-73; PMID:23995617; http://dx.doi.org/10.4161/mabs.26233
178. Davis JH, Aperlo C, Kurosawa E, Lan Y, Lo KM, Huston JS. SEEDbodies:fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
179. Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Scheickhardt R, Dugas M, Soloviev M, Bernhardt A, Fischer D, et al. Therapeutic assessment of SEED:a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel 2011; 24:447-54; PMID:21498564; http://dx.doi.org/10.1093/protein/gzq123
180. Kelton C, Wesolowski JS, Soloviev M, Schweickhardt R, Fischer D, Kurosawa E, McKenna SD, Gross AW. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule. Arch Biochem Biophys 2012; 526:219-25; PMID:22426455; http://dx.doi.org/10.1016/j.abb.2012.03.005
181. Moretti P, Skegro D, Ollier R, Wassmann P, Aebischer C, Laurent T, et al. BEAT the bispecific challenge:a novel and efficient platform for the expression of bispecific IgGs. BMC Proceedings 2013; 7(Suppl 6):O9
182. Croset A, Macoin J, Ollier R, Pluess M, Delon C, Skegro D, et al. GBR1302:a BEAT bispecific antibody for the treatment of HER2 positive cancers. Eur J Cancer 2014; 50 Suppl 6:48; http://dx.doi.org/10.1016/S0959-8049(14)70265-5
183. Leaver-Fey A, Froning KJ, Atwell S, Aldaz H, Pustilnik A, Lu F, Huang F, Yuan R, Hassanali S, Chamberlain AK, et al. Computationally Designed Bispecific Antibodies using Negative State Repertoires. Structure 2016; 24:641-51; PMID:26996964; http://dx.doi.org/10.1016/j.str.2016.02.013
184. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32:191-8; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
185. Wranik BJ, Christensen EL, Schaefer G, Jackman JK, Vendel AC, Eaton D. LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J Biol Chem 2012; 287:43331-9; PMID:23118228; http://dx.doi.org/10.1074/jbc.M112.397869
186. Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 2015; 5:17943; PMID:26659273; http://dx.doi.org/10.1038/srep17943
187. Tustian AD, Endicott C, Adams B, Mattila J, Bak H. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. MAbs 2016; 8:828-38; PMID:26963837; http://dx.doi.org/10.1080/19420862.2016.1160192
188. Fischer N, Elson G, Magistrelli G, Dheilly E, Fougue N, Laurendon A, Gueneau F, Ravn U, Depoisier JF, Moine V, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun 2015; 6:6613; PMID:25672245; http://dx.doi.org/10.1038/ncomms7113
189. Xu L, Yee H, Chan C, Kashyap AK, Horowitz L, Horowitz M, Bhatt RR, Lerner RA. Combinatorial surrobody libraries. Proc Natl Acad Sci USA 2008; 105:10756-61; PMID:18664586; http://dx.doi.org/10.1073/pnas.0805293105
190. Foreman PK, Gore M, Kobel PA, Xu L, Yee H, Hannum C, Ho H, Wang SM, Tran HV, Horowitz M, et al. ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11:1411-20; PMID:22553357; http://dx.doi.org/10.1158/1535-7163.MCT-12-0068
191. Milutinvic S, Kashyap AK, Yanagi T, Wimer C, Zhou S, O'Neill R, Kurtzman AL, Faynboym A, Xu L, Hannum CH, et al. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. Mol Cancer Ther 2016; 15:114-24; PMID:26516157; http://dx.doi.org/10.1158/1535-7163.MCT-15-0400
192. Lee HS, Shu L, De Pascalis R, Giuliano M, Zhu M, Padlan EA, Hand PH, Schlom J, Hong HJ, Kashmiri SV. Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Mol Immunol 1999; 36:61-71; PMID:10369421
193. Hust M, Jostock T, Menzel C, Voedisch B, Mohr A, Brenneis M, Kirsch MI, Meier D, Dübel S. Single chain Fab (scFab) fragments. BMC Biotechnol 2007; 7:14; PMID:17346344; http://dx.doi.org/10.1186/1472-6750-7-14
194. Schirrmann T, Menzel C, Hust M, Prilop J, Jostock T, Dübel S. Oligomeric forms of single chain immunoglobulin (scIgG). MAbs 2010; 2:73-76; PMID:20081378
195. Koerber JT, Hornsby MJ, Wells JA. An improved single-chain Fab platform for efficient display and recombinant expression. J Mol Biol 2015; 427:576-86; PMID:25481745; http://dx.doi.org/10.1016/j.jmb.2014.11.017
196. Castoldi R, Schanzer J, Panke C, Jucknischke U, Neubert NJ, Croasdale R, Scheuer W, Auer J, Klein C, Niederfellner G, et al. TetraMabs:simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Eng Des Sel 2016; PMID:27578890; http://dx.doi.org/10.1093/protein/gzw037
197. Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schazer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 4:653-663; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379
198. Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA 2016; 113:4476-81; PMID:27044098; http://dx.doi.org/10.1073/pnas.1525360113
199. Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, Gajjar MR, Sun M, Seaman MS, Padte NN, et al. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell 2016; 165:1621-31; PMID:27315479; http://dx.doi.org/10.1016/j.cell.2016.05.024
200. Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs 2016; 8:1010-20; PMID:27285945; http://dx.doi.org/10.1080/19420862.2016.1197457
201. Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Quaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clin Cancer Res 2016; 22:3286-97; PMID:26861458; http://dx.doi.org/10.1158/1078-0432.CCR-15-1696
202. Hu S, Fu W, Xu W, Yang Y, Cruz M, Berezov SD, Jorissen D, Takeda H, Zhu W. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res 2014; 75:159-70; PMID:25371409; http://dx.doi.org/10.1158/0008-5472.CAN-14-1670
203. Wu X, Sereno AJ, Huang F, Zhang K, Batt M, Fitchett JR, He D, Rick HL, Conner EM, Demarest SJ. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. MAbs 2015; 7:364-76; PMID:25611120; http://dx.doi.org/10.1080/19420862.2015.1007826
204. Golay J, Choblet S, Iwaszkiewicz J, Cerutti P, Ozil A, Loisel S, Pugnière M, Ubiali G, Zoete V, Michielin O, et al. Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies. J Immunol 2016; 196:3199-211; PMID:26921308; http://dx.doi.org/10.4049/jimmunol.1501592
205. Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 2015; 7:377-89; PMID:25621507; http://dx.doi.org/10.1080/19420862.2015.1007816
206. Mazor Y, Hansen A, Yang C, Chowdhury PS, Wang J, Stephens G, Wu H, Dall'Acqua WF. Insights into the molecular basis of a bispecific antibody's target selectivity. MAbs 2015; 7:461-669; PMID:25730144; http://dx.doi.org/10.1080/19420862.2015.1022695
207. Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, et al. Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer. Antibodies 2016; 5:6, doi:10.3390/antib5010006
208. Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009; 393:672-92; PMID:19699208; http://dx.doi.org/10.1016/j.jmb.2009.08.032
209. Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother 2011; 55:2369-78; PMID:21300827; http://dx.doi.org/10.1128/AAC.00215-10
210. Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys 2012; 526:206-18; PMID:22464987; http://dx.doi.org/10.1016/j.abb.2012.03.016
211. Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, Poku E, Li L, Andersen JT, Sandlie I, et al. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting:comparison of tumor uptake and blood clearance. Protein Eng Des Sel 2013; 26:187-93; PMID:23175797; http://dx.doi.org/10.1093/protein/gzs096
212. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, Wittrup KD. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010; 23:221-8; PMID:20019028; http://dx.doi.org/10.1093/protein/gzp077
213. Zuo Z, Jimenez X, Witte L, Zhu Z. An efficient route to the production of an IgG-like bispecific antibody. Protein Eng 2000; 13:361-7; PMID:10835110
214. Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279:2856-65; PMID:14576153; http://dx.doi.org/10.1074/jbc.M310132200.
215. Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, et al. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 2007; 282:27659-65; PMID:17644522
216. Watanabe Y, Asano R, Arai K, Shimomura I, Ogata H, Kawaguchi H, Hayashi H, Ohtsuka H, Yoshida H, Katayose Y, et al. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. Oncol Rep 2011; 26:949-55; PMID:21743971; http://dx.doi.org/10.3892/or.2011.1382
217. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbR. MAbs 2009; 1:128-41; PMID:20061822
218. Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, Georges G, Josel HP, Dziadek S, Hopfner KP, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci USA 2011; 108:8194-9; PMID:21536919; http://dx.doi.org/10.1073/pnas.1018565108
219. Kang JC, Poovassery JS, Bansal P, You S, Manjarres IM, Ober RJ, Ward ES. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. MAbs 2014; 6:340-53; PMID:24492289; http://dx.doi.org/10.4161/mabs.27658
220. Grote M, Haas AK, Klein C, Schaefer W, Brinkmann U. Bispecific antibody derivatives based on full-length IgG formats. Methods Mol Biol 2012; 901:247-63; PMID:22723106; http://dx.doi.org/10.1007/978-1-61779-931-0_16
221. Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 2009; 23:115-27; PMID:20022918; http://dx.doi.org/10.1093/protein/gzp073
222. Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286:47034717; PMID:21123183; http://dx.doi.org/10.1074/jbc.M110.184317
223. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotpyes:from structure to effector functions. Front Immunol 2014; 5:520; PMID:25368619; http://dx.doi.org/10.3389/fimmu.2014.00520
224. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028
225. Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011b; 3:273-88; PMID:21393993
226. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. 1999; 29:2613-24; PMID:10458776
227. Wines BD, Powell MS, Parren PW, Barnes N, Hogarth PM. The IgG Fc contains distinct Fc receptor (FcR) binding sites:the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J Immunol 2000; 164:5313-8; PMID:10799893
228. Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64:700-4; PMID:18560159; http://dx.doi.org/10.1107/S0907444908007877
229. Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 2013; 65:114-26; PMID:23872058; http://dx.doi.org/10.1016/j.ymeth.2013.06.035
230. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006; 58:640-56; PMID:16904789; http://dx.doi.org/10.1016/j.addr.2006.01.026
231. An Z, Forrest G, Moore R, Cukan M, Haytko P, Vitelli S, Zhao JZ, Lu P, Hua J, Gibson CR, et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs 2009; 1:572-9; PMID:20073128
232. Poovassery JS, Kang JC, Kim D, Ober RJ, Ward ES. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer. Int J Cancer 2015; 137:267-77; PMID:25471734; http://dx.doi.org/10.1002/ijc.29378
233. Boado RJ, Zhou QH, Lu JZ, Hui EK, Pardidge WM. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm 2010; 7:237-44; PMID:19921848; http://dx.doi.org/10.1021/mp900235k
234. Lu CY, Chen GJ, Tai PH, Yang YC, Hsu YS, Chang M, Hsu CL. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma. Biochem Biophys Res Commun 2016; 473:808-813; PMID:27040766; http://dx.doi.org/10.1016/j.bbrc.2016.03.124
235. Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung NK. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther 2014; 13:1803-12; PMID:24944121; http://dx.doi.org/10.1158/1535-7163.MCT-13-0933
236. Shen J, Vil MD, Jimenez X, Iacolina M, Zhang H, Zhu Z. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J Biol Chem 2006; 281:10706-14; PMID:16481314; http://dx.doi.org/10.1074/jbc.M513415200
237. Shen J, Vil MD, Jimenez X, Zhang H, Iacolina M, Mangalampalli V, Balderes P, Ludwig DL, Zhu Z. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods 2007; 318:65-74; PMID:17126853; http://dx.doi.org/10.1016/j.jim.2006.09.020
238. Brack S, Attinger-Toller I, Schade B, Mourlane F, Klupsch K, Woods R, Hachemi H, von der Bey U, Koenig-Friedrich S, Bertschinger J, et al. A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Mol Cancer Ther 2014; 13:2030-9; PMID:24994770; http://dx.doi.org/10.1158/1535-7163.MCT-14-0046-T
239. Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs 2016; 8:141-149; PMID:26390837; http://dx.doi.org/10.1080/19420862.2015.1093266
240. Kanakaraj P, Puffer BA, Yao XT, Kankanala S, Boyd E, Shah RR, Wang G, Patel D, Krishnamurthy R, Kaithamana S, et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012; 4:600-613; PMID:22864384; http://dx.doi.org/10.4161/mabs.21227
241. LaFleur DW, Abramyan D, Kanakaraj P, Smith RG, Shah RR, Wang G, Yao XT, Kankanala S, Boyd E, Zaritskaya L, et al. Monoclonal antibody therapeutics with up to five specificities:functional enhancement through fusion of target-specific peptides. MAbs 2013; 5:208-218; PMID:23575268; http://dx.doi.org/10.4161/mabs.23043
242. Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, et al. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. MAbs 2015; 7:931-45; PMID:26073904; http://dx.doi.org/10.1080/19420862.2015.1055442
243. Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, et al. Design, construction, and in vitro analysis of multivalent antibodies. J Immunol 2003; 170:4854-61; PMID:12728922
244. Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, et al. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. Mol Cancer Ther 2016; 15:946-57; PMID:27037412; http://dx.doi.org/10.1158/1535-7163.MCT-15-0647
245. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics:1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009; 113:6161-71; PMID:19372261; http://dx.doi.org/10.1182/blood-2008-10-187138
246. Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH. Dual-targeting immunotherapy of lymphoma:potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 2012; 119:3767-2778; PMID:22271448; http://dx.doi.org/10.1182/blood-2011-09-381988
247. Rossi EA, Goldenberg DM, Chang CH. The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 2012; 23:309-23; PMID:22168393; http://dx.doi.org/10.1021/bc2004999
248. Gupta P, Goldenberg DM, Rossi EA, Chang CH. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 2010; 116:3258-67; PMID:20628151; http://dx.doi.org/10.1182/blood-2010-03-276857
249. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
250. Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, Ghayur T. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009; 1:339-47; PMID:20068402
251. Lacy SE, Wu C, Ambrosi DJ, Hsieh CM, Bose S, Miller R, Conlon DM, Tarcsa E, Chari R, Ghayur T, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs 2015; 7:605-19; PMID:25764208; http://dx.doi.org/10.1080/19420862.2015.1026501
252. Craig RB, Summa CM, Corti M, Pincus SH. Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. PLoS One 2012; 7:e46778; PMID:23056448; http://dx.doi.org/10.1371/journal.pone.0046778
253. Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K, Majeti R. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 2015; 7:946-56; PMID:26083076; http://dx.doi.org/10.1080/19420862.2015.1062192
254. Gu J, Yang J, Chang Q, Liu Z, Ghayur T, Gu J. Identification of anti-EGFR and anti-ErbB3 dual variable domains immunoglobulin (DVD-Ig) proteins with unique activities. PLoS One 2015; 20:e0124135; PMID:25997020; http://dx.doi.org/10.1371/journal.pone.0124135
255. Zeng J, Liu R, Wang J, Fang Y. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR. J Cancer Res Clin Oncol 2015; 141:1899-907; PMID:25773122; http://dx.doi.org/10.1007/s00432-015-1949-7
256. Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M, Ghayur T, Gu J. Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities. PLoS One 2014; 9:e97292; PMID:24824849; http://dx.doi.org/10.1371/journal.pone.0097292
257. DiGiammarino EL, Harlan JE, Walter KA, Ladror US, Edalji RP, Hutchings CW, Lake MR, Greischar AJ, Liu J, Ghayur T, et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. MAbs 2011; 3:487-494; PMID:21814039; http://dx.doi.org/10.4161/mabs.3.5.16326
258. Correia I, Sung J, Burton R, Jakob CG, Carragher B, Ghayur T, Radziejewski C. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. MAbs 2013; 5:364-72; PMID:23572180; http://dx.doi.org/10.4161/mabs.24258
259. Jacob CG, Edalji R, Judge RA, diGiammarino E, Li Y, Gu J, Ghayur T. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule. MAbs 2013; 5:358-63; PMID:23549062; http://dx.doi.org/10.4161/mabs.23977
260. Onuoha SC, Ferrari M, Sblattero D, Pfizalis C. Rational design of antirheumatoic prodrugs specific for sites of inflammation. Arthritis Rheumatol 2015; 67:2661-72; PMID:26097196; http://dx.doi.org/10.1002/art.39232
261. Steinmetz A, Vallée F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs 2016; 8:867-78; PMID:26984268; http://dx.doi.org/10.1080/19420862.2016.1162932
262. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-4; PMID:19299620; http://dx.doi.org/10.1126/science.1165480
263. Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One 2011; 6:e17887; PMID:21526167; http://dx.doi.org/10.1371/journal.pone.0017887
264. Lee CV, Koenig P, Fuh G. A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions. MAbs 2014; 6:622-7; PMID:24618680; http://dx.doi.org/10.4161/mabs.28483
265. Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2012; 73:824-33; PMID:23172311; http://dx.doi.org/10.1158/0008-5472.CAN-12-1611
266. Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messerschmith W, Blumenschein GR, Jr, Tabernero J, Roda D, Calles A, Jimeno A, et al. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res 2015; 21:2462-70; PMID:26034219; http://dx.doi.org/10.1158/1078-0432.CCR-14-2412
267. Beckmann R. Dual targeting. 2012; WO2012163520 A1
268. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains:Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010; 23:289-297; PMID:20150180; http://dx.doi.org/10.1093/protein/gzq005
269. Wozniak-Knopp G, Stadlmann J, Rüker F. Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds. PLoS One 2012; 7:e30083; PMID:22272277; http://dx.doi.org/10.1371/journal.pone.0030083
270. Traxlmayr MW, Faissner M, Stadlmayr G, Hasenhindl C, Antes B, Rüker F, Obinger C. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast. Biochim Biophys Acta 2012; 1824:542-9; PMID:22285845; http://dx.doi.org/10.1016/j.bbapap.2012.01.006
271. Traxlmayr MW, Lobner E, Antes B, Kainer M, Wiederkum S, Hasenhindl C, Stadlmayr G, Rüker F, Woisetschläger M, Moulder K, et al. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display. Protein Eng Des Sel 2013; 26:255-65; PMID:23267121; http://dx.doi.org/10.1093/protein/gzs102
272. Fennell BJ, McDonnell B, Tam AS, Chang L, Steven J, Broadbent ID, Gao H, Kieras E, Alley J, Luxenberg D, et al. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery. MAbs 2013; 5:882-95; PMID:23995618; http://dx.doi.org/10.4161/mabs.26201
273. Connelly RJ, Hayden MS, Scholler JK, Tsu TT, Dupont B, Ledbetter JA, Kanner SB. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes. Int Immunol 1998; 10:1863-72; PMID:9885907
274. Kim H, Park S, Lee HK, Chung J. Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification. Exp Mol Med 2013; 45:e43; PMID:24071736; http://dx.doi.org/10.1038/emm.2013.83
275. Yoon S, Kim YH, Kang SH, Kim SK, Lee HK, Kim H, Chung J, Kim IH. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts. J Cancer Res Clin Oncol 2014; 140:227-33; PMID:24292501; http://dx.doi.org/10.1007/s00432-013-1548-4
276. Natsume A, Wakitani M, Yamne-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. J Biochem 2006; 140:359-68; PMID:16861252; http://dx.doi.org/10.1093/jb/mvj157
277. Wu SC, Chen YJ, Wang HC, Chou MY, Chang TY, Yuan SS, Chen CY, Hou MF, Hsu JT, Wang YM. Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors. Theranostics 2016; 6:118-30; PMID:26722378; http://dx.doi.org/10.7150/thno.13069
278. He Y, Hendriks D, van Ginkel R, Samplonius D, Bremer E, Helfrich W. Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5. J Invest Dermatol 2016; 136:541-4; PMID:26967487; http://dx.doi.org/10.1016/j.jid.2015.11.009
279. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 2014; 6:262ra155; PMID:25391481; http://dx.doi.org/10.1126/scitranslmed.3009655
280. François B, Chastre J, Eggiman P, Laterre PF, Torres A, Sanchez M, Esser MT, Bishop B, Bonten M, Goosens H, Jafri HS. The SAATELLITE and EVADE clinical studies within the COMBACTE Consortium:A public-private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent nosocomial pneumonia. Clin Infect Dis 2016; 63 Suppl 2:S46-51. doi:10.1093/cid/ciw245
281. Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, Bohlen P, Witte L, Zhu Z. Di-diabody:a novel tetravalent bispecific antibody molecule by design. J Immunol Methods 2003; 279:219-32; PMID:12969563
282. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280:19665-72; PMID:15757893; http://dx.doi.org/10.1074/jbc.M500815200
283. Alt M, Müller R, Kontermann RE. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 1999; 454:90-4; PMID:10413102
284. Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, Kontermann RE. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs 2016; 8:120-8; PMID:26514880; http://dx.doi.org/10.1080/19420862.2015.1113360
285. Wang L, He Y, Zhang G, Ma J, Liu C, He W, Wang W, Han H, Boruah BM, Gao B. Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody. PLoS One 2013; 8:e75589. PMID:24086580; http://dx.doi.org/10.1371/journal.pone.0075589
286. Seifert O, Plappert A, Heidel N, Fellermeier S, Messerschmidt SK, Richter F, Kontermann RE. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. Protein Eng Des Sel 2012; 25:603-12; PMID:22988132; http://dx.doi.org/10.1093/protein/gzs059
287. Schuurman J, Parren PW. Editorial overview:special section:New concepts in antibody therapeutics:What's in store for antibody therapy. Curr Opin Immunol 2016; 40:VII-XIII; PMID:27083411; http://dx.doi.org/10.1016/j.coi.2016.04.001
288. Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies:what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 2012; 8:141-60; PMID:22248267; http://dx.doi.org/10.1517/17425255.2012.643868
289. Sockolosky JT, Szoka FC. The neonatal Fc receptor, FcRn, as a target for drug delivry and therapy. Adv Drug Deliv Rev 2015; 91:109-24; PMID:25703189; http://dx.doi.org/10.1016/j.addr.2015.02.005
290. Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therpaeutic antibodies. J Pharm Sci 2015; 104:1885-98; PMID:25821140; http://dx.doi.org/10.1002/jps.24430
291. Razinkov VI, Treuheit MJ, Becker GW. Accelerated formulation development of monoclonal antibodies (mAbs) an mAb-based modalities:a review of methods and tools. J Biomol Screen 2015; 20:468-83; PMID:25576149; http://dx.doi.org/10.1177/1087057114565593
292. Mould DR, Meibohm B. Drug development of therapeutic monoclonal antibodies. BioDrugs 2016; 30:275-93; PMID:27342605; http://dx.doi.org/10.1007/s40259-016-0181-6
293. Dashivets T, Stracke J, Dengl S, Knaupp A, Pollmann J, Buchner J, Schlothauer T. Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies. MAbs 2016; PMID:27612038
294. Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, Beck H, Emrich T, Harris RJ. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals 2016; 44:291-305; http://dx.doi.org/10.1016/j.biologicals.2016.06.005
295. Haberger M, Heidenreich AK, Schlothauer T, Hook M, Gassner J, Bomans K, Yegres M, Zwick A, Zimmermann B, Wegele H, et al. Functional assessment of antibody oxidation by native mass spectrometry. MAbs 2015; 7:891-900; PMID:26000623; http://dx.doi.org/10.1080/19420862.2015.1052199
296. Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B, et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies:Susceptibility vs. functionality of critical quality attributes. MAbs 2014; 6:327-39; PMID:2444108; http://dx.doi.org/10.4161/mabs.27876
297. Walters BT, Jensen PF, Larraillet V, Lin K, Patapoff T, Schlothauer T, Rand KD, Zhang J. Conformational destabilization of immunoglobulin G increases the low pH binding affinity with the neonatal Fc receptor. J Biol Chem 2016; 291:1817-25; PMID:26627822; http://dx.doi.org/10.1074/jbc.M115.691568